Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2018

View Archived Issues

Virpax signs license agreement to use LipoCure's liposome drug delivery technology

Microbiotica and Genentech enter strategic collaboration for IBD

FDA grants rare pediatric disease designation to CLR-131 for the treatment of rhabdomyosarcoma

Intra-Cellular initiates rolling submission of NDA for lumateperone

Moleculin Biotech enters agreement to develop formulation for its STAT3 inhibitor

Alkermes receives payment from Biogen related to BIIB-098 program

Effects on gut microbiome seen with Blautix in irritable bowel syndrome patients

S1P regulation key for bone quality and may constitute a therapeutic target in osteoporosis

Shandong Luoxin Pharmacy Group, Luoxin Biotechnology Shanghai Co. patent BRD4/1/2 inhibitors

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery identify HBV cccDNA inhibitors

New RORC modulators divulged by Bristol-Myers Squibb

Weishang Shanghai Bio-Pharmaceutical discovers mutant EGFR inhibitors

Merck & Co. synthesizes new FXIIa inhibitors

Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL

ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients

First healthy volunteers enrolled in phase I study of BTRX-335140

Positive results presented from ongoing phase I trial of PTI-801 in patients with CF

4D pharma and MSD collaborate to study Keytruda and MRx-0518 combination in solid tumors

FDA grants orphan drug designation to TransCon PTH

EMA grants PRIME designation for dilanubicel

Athersys expands its collaboration with Healios

Phase II results presented for TAK-954 in patients with enteral feeding intolerance

GlaxoSmithKline initiates phase I study of GSK-3858279

Enrollment ongoing in phase III study of pertuzumab and trastuzumab fixed-dose combination

Selinexor liposarcoma trial advances after improvement seen in progression-free survival

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...